Evidence map›Paper›PMID 35663739›Full record

ReviewHeliyon2022

Lipid-based nanoparticles for treatment of cancer.

Sumit Sheoran, Swati Arora, R Samsonraj, Pilli Govindaiah, Sugunakar Vuree

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 115 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Drug Delivery Systems for Natural Medicines in Cancer Therapy.Current topics in medicinal chemistry · 2025
    Review
  20. Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Sumit SheoranDept. of Biochemistry, School of Biosciences and Bioengineering, Lovely Professional University, Jalandhar.
Swati AroraDept. of Biotechnology and Bioinformatics, School of Biosciences and Bioengineering, Lovely Professional University, Jalandhar.
R SamsonrajDept. of Molecular Biology, School of Biosciences and Bioengineering, Lovely Professional University, Jalandhar.
Pilli GovindaiahDept. of Pharmaceutical Chemistry, School of Pharmacy, Lovely Professional University, Jalandhar.
Sugunakar VureeDepartment of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, 144111 Punjab, India.
Lovely Professional University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Investigators were continuously creating novel nanotechnologies to address unmet requirements throughout the administration of therapeutic medicines & imaging agents for cancer treatment & diagnostics, appropriately. LNPs(Lipid nanoparticles) are legitimate particulates (approx. 100 nm in size) gathered from various lipid as well as other biochemical compounds which overall functionality to resolve biological barriers (biobarriers), allowing LNPs to selectively collect somewhere outside of disease-target cells again for responsive therapeutics. Most pharmaceutically important compounds were insoluble throughout water solutions, were chemical & physiologically unstable, or have toxicities. Among the most potential drug carrier for bioactive organic compounds is LBNPs (Lipid based nanoparticles) technologies. Its present use in chemotherapy have transformed treatment for cancer by increasing the antitumor effect of a number of chemotherapeutics. Because they may be created using naturally occurring sources, LBNPs have great temporal and thermal stability, maximum load potential, simplicity of preparations, cheap manufacturing costs, & big manufacturing output. Furthermore, combining chemotherapeutic drugs with LNPs reduces active therapeutic dosage and toxicities, lowers treatment resistance, & raises drug concentration in tumour cells while reducing concentrations in normal tissue. LBNPs were widely studied in cancer treatment, both in vitro and in vivo, with encouraging outcomes in certain clinical trials. This study provides an overview of the many types of LBNPs which have been created in latest years and their applications and contributions in different types of cancers.

Indexed as

Clinical trialsLipid based NanopartclesLiposomesSolid lipid nanoparticlesTumour

Identifiers

PMID35663739
PMCPMC9160046
OpenAlexW4280489728

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.